Alteplase (injection)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gerald Chi
Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Overview
Alteplase (injection) is a thrombolytic agent that is FDA approved for the {{{indicationType}}} of acute myocardial infarction (AMI) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with AMI. Alteplase is also indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence of disability and the management of acute massive pulmonary embolism (PE) in adults. Common adverse reactions include hemorrhage.
Adult Indications and Dosage
FDA-Labeled Indications and Dosage (Adult)
Acute Myocardial Infarction
- Dosing Information
- Dosage
Acute Ischemic Stroke
- Dosing Information
- Dosage
Pulmonary Embolism
- Dosing Information
- Dosage
Condition4
- Dosing Information
- Dosage
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Alteplase (injection) in adult patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Alteplase (injection) in adult patients.
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding FDA-Labeled Use of Alteplase (injection) in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition1
- Developed by:
- Class of Recommendation:
- Strength of Evidence:
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Alteplase (injection) in pediatric patients.
Non–Guideline-Supported Use
Condition1
- Dosing Information
- Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Alteplase (injection) in pediatric patients.
Contraindications
- Condition1
Warnings
- Description
Precautions
- Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Alteplase (injection) in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Alteplase (injection) in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Drug Interactions
- Drug
- Description
Use in Specific Populations
Pregnancy
- Pregnancy Category
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Alteplase (injection) in women who are pregnant.
Labor and Delivery
There is no FDA guidance on use of Alteplase (injection) during labor and delivery.
Nursing Mothers
There is no FDA guidance on the use of Alteplase (injection) with respect to nursing mothers.
Pediatric Use
There is no FDA guidance on the use of Alteplase (injection) with respect to pediatric patients.
Geriatic Use
There is no FDA guidance on the use of Alteplase (injection) with respect to geriatric patients.
Gender
There is no FDA guidance on the use of Alteplase (injection) with respect to specific gender populations.
Race
There is no FDA guidance on the use of Alteplase (injection) with respect to specific racial populations.
Renal Impairment
There is no FDA guidance on the use of Alteplase (injection) in patients with renal impairment.
Hepatic Impairment
There is no FDA guidance on the use of Alteplase (injection) in patients with hepatic impairment.
Females of Reproductive Potential and Males
There is no FDA guidance on the use of Alteplase (injection) in women of reproductive potentials and males.
Immunocompromised Patients
There is no FDA guidance one the use of Alteplase (injection) in patients who are immunocompromised.
Administration and Monitoring
Administration
- Oral
- Intravenous
Monitoring
There is limited information regarding Monitoring of Alteplase (injection) in the drug label.
Condition1
- Description
IV Compatibility
There is limited information regarding IV Compatibility of Alteplase (injection) in the drug label.
Overdosage
Acute Overdose
Signs and Symptoms
- Description
Management
- Description
Chronic Overdose
There is limited information regarding Chronic Overdose of Alteplase (injection) in the drug label.
Pharmacology
There is limited information regarding Alteplase (injection) Pharmacology in the drug label.
Mechanism of Action
Structure
Pharmacodynamics
There is limited information regarding Pharmacodynamics of Alteplase (injection) in the drug label.
Pharmacokinetics
There is limited information regarding Pharmacokinetics of Alteplase (injection) in the drug label.
Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Alteplase (injection) in the drug label.
Clinical Studies
There is limited information regarding Clinical Studies of Alteplase (injection) in the drug label.
Condition1
- Description
How Supplied
Storage
There is limited information regarding Alteplase (injection) Storage in the drug label.
Images
Drug Images
{{#ask: Page Name::Alteplase (injection) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}
Package and Label Display Panel
{{#ask: Label Page::Alteplase (injection) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}
Patient Counseling Information
There is limited information regarding Patient Counseling Information of Alteplase (injection) in the drug label.
Precautions with Alcohol
- Alcohol-Alteplase (injection) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
Brand Names
Look-Alike Drug Names
Drug Shortage Status
Price
References
The contents of this FDA label are provided by the National Library of Medicine.
- ↑ "ACTIVASE (alteplase) kit".
- ↑ "CATHFLO ACTIVASE (alteplase) injection, powder, lyophilized, for solution".
- ↑ 3.0 3.1 "http://www.ismp.org". External link in
|title=
(help)
{{#subobject:
|Page Name=Alteplase (injection) |Pill Name=No image.jpg |Drug Name= |Pill Ingred=|+sep=; |Pill Imprint= |Pill Dosage= |Pill Color=|+sep=; |Pill Shape= |Pill Size (mm)= |Pill Scoring= |Pill Image= |Drug Author= |NDC=
}}
{{#subobject:
|Label Page=Alteplase (injection) |Label Name=Alteplase (injection)09.png
}}
{{#subobject:
|Label Page=Alteplase (injection) |Label Name=Alteplase (injection)10.png
}}
{{#subobject:
|Label Page=Alteplase (injection) |Label Name=Alteplase (injection)11.png
}}
{{#subobject:
|Label Page=Alteplase (injection) |Label Name=Alteplase (injection)12.png
}}